ABBVIE INC (4AB.DE) Stock Fundamental Analysis

FRA:4AB • US00287Y1091

197.6 EUR
+7.6 (+4%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

4AB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 78 industry peers in the Biotechnology industry. 4AB has a medium profitability rating, but doesn't score so well on its financial health evaluation. 4AB is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • 4AB had positive earnings in the past year.
  • 4AB had a positive operating cash flow in the past year.
  • Of the past 5 years 4AB 4 years were profitable.
  • 4AB had a positive operating cash flow in 4 of the past 5 years.
4AB.DE Yearly Net Income VS EBIT VS OCF VS FCF4AB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

  • 4AB has a Return On Assets of 1.75%. This is in the better half of the industry: 4AB outperforms 75.31% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.64%, 4AB belongs to the best of the industry, outperforming 91.36% of the companies in the same industry.
  • 4AB had an Average Return On Invested Capital over the past 3 years of 13.67%. This is above the industry average of 11.66%.
  • The last Return On Invested Capital (15.64%) for 4AB is above the 3 year average (13.67%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROIC 15.64%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
4AB.DE Yearly ROA, ROE, ROIC4AB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • 4AB has a better Profit Margin (3.94%) than 77.78% of its industry peers.
  • In the last couple of years the Profit Margin of 4AB has declined.
  • 4AB's Operating Margin of 33.05% is amongst the best of the industry. 4AB outperforms 88.89% of its industry peers.
  • In the last couple of years the Operating Margin of 4AB has declined.
  • 4AB has a Gross Margin (71.16%) which is in line with its industry peers.
  • 4AB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
4AB.DE Yearly Profit, Operating, Gross Margins4AB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 4AB is still creating some value.
  • 4AB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
4AB.DE Yearly Shares Outstanding4AB.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
4AB.DE Yearly Total Debt VS Total Assets4AB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • 4AB has an Altman-Z score of 2.51. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
  • 4AB has a Altman-Z score of 2.51. This is in the better half of the industry: 4AB outperforms 67.90% of its industry peers.
  • The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of 4AB (3.49) is better than 80.25% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Altman-Z 2.51
ROIC/WACC1.32
WACC11.88%
4AB.DE Yearly LT Debt VS Equity VS FCF4AB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • 4AB has a Current Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 4AB has a worse Current ratio (0.72) than 77.78% of its industry peers.
  • 4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of 4AB (0.60) is worse than 76.54% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.6
4AB.DE Yearly Current Assets VS Current Liabilites4AB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for 4AB have decreased by -1.19% in the last year.
  • Measured over the past years, 4AB shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.99% on average per year.
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%

3.2 Future

  • 4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.77% yearly.
  • Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 6.33% on average per year.
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.77%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.33%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
4AB.DE Yearly Revenue VS Estimates4AB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
4AB.DE Yearly EPS VS Estimates4AB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 23.44, 4AB is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Earnings ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 83.95% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.68, 4AB is valued at the same level.
  • Based on the Price/Forward Earnings ratio of 16.14, the valuation of 4AB can be described as correct.
  • Based on the Price/Forward Earnings ratio, 4AB is valued cheaply inside the industry as 95.06% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. 4AB is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 23.44
Fwd PE 16.14
4AB.DE Price Earnings VS Forward Price Earnings4AB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 4AB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 4AB is cheaper than 80.25% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 88.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 21.05
EV/EBITDA 16.93
4AB.DE Per share data4AB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • 4AB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 4AB has a very decent profitability rating, which may justify a higher PE ratio.
  • 4AB's earnings are expected to grow with 21.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3Y21.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • 4AB has a Yearly Dividend Yield of 3.04%.
  • Compared to an average industry Dividend Yield of 0.50, 4AB pays a better dividend. On top of this 4AB pays more dividend than 97.53% of the companies listed in the same industry.
  • 4AB's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
Industry RankSector Rank
Dividend Yield 3.04%

5.2 History

  • The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
4AB.DE Yearly Dividends per share4AB.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • 489.69% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
  • The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
4AB.DE Yearly Income VS Free CF VS Dividend4AB.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
4AB.DE Dividend Payout.4AB.DE Dividend Payout, showing the Payout Ratio.4AB.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ABBVIE INC

FRA:4AB (2/13/2026, 7:00:00 PM)

197.6

+7.6 (+4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-04
Earnings (Next)04-23
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap349.23B
Revenue(TTM)N/A
Net Income(TTM)2.35B
Analysts77.3
Price Target213.99 (8.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.04%
Yearly Dividend5.26
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)0.49%
PT rev (3m)2.15%
EPS NQ rev (1m)-18.13%
EPS NQ rev (3m)-21.02%
EPS NY rev (1m)-6.64%
EPS NY rev (3m)-5.77%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
Industry RankSector Rank
PE 23.44
Fwd PE 16.14
P/S 6.95
P/FCF 21.05
P/OCF 19.86
P/B N/A
P/tB N/A
EV/EBITDA 16.93
EPS(TTM)8.43
EY4.27%
EPS(NY)12.24
Fwd EY6.2%
FCF(TTM)9.39
FCFY4.75%
OCF(TTM)9.95
OCFY5.04%
SpS28.45
BVpS-1.26
TBVpS-44.16
PEG (NY)0.52
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROCE 20.86%
ROIC 15.64%
ROICexc 16.59%
ROICexgc 572.43%
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
FCFM 33%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Debt/EBITDA 2.39
Cap/Depr 14.25%
Cap/Sales 1.97%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 838.33%
Current Ratio 0.72
Quick Ratio 0.6
Altman-Z 2.51
F-Score7
WACC11.88%
ROIC/WACC1.32
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.33%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year-0.19%
EBIT Next 3Y15.91%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / 4AB.DE FAQ

What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 4AB.DE.


What is the valuation status for 4AB stock?

ChartMill assigns a valuation rating of 7 / 10 to ABBVIE INC (4AB.DE). This can be considered as Undervalued.


How profitable is ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a profitability rating of 5 / 10.


Can you provide the financial health for 4AB stock?

The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.


How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?

The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.